NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or ...
Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk ...
GREAT BARRINGTON — The Triplex Cinema has launched a new capital campaign, "Save The Triplex: Part 2," to replace its faulty HVAC system, upgrade seating and sound, and restore Theater 2, the fourth ...
Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...
First prophylactic vaccine to demonstrate proof of concept for CMV control independent of human leukocyte antigen (HLA) status in stem cell transplant recipients DUARTE, Calif.--(BUSINESS WIRE)--City ...
MIAMI, June 15, 2023 (GLOBE NEWSWIRE) -- Helocyte, Inc. (“Helocyte”), a subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO), today announced that the National Cancer Institute (“NCI”) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback